Tocilizumab for patients with COVID-19 pneumonia. The single-arm TOCIVID-19 prospective trial

Posted on 22.10.2020 - 03:28
Abstract Background Tocilizumab blocks pro-inflammatory activity of interleukin-6 (IL-6), involved in pathogenesis of pneumonia the most frequent cause of death in COVID-19 patients. Methods A multicenter, single-arm, hypothesis-driven trial was planned, according to a phase 2 design, to study the effect of tocilizumab on lethality rates at 14 and 30 days (co-primary endpoints, a priori expected rates being 20 and 35%, respectively). A further prospective cohort of patients, consecutively enrolled after the first cohort was accomplished, was used as a secondary validation dataset. The two cohorts were evaluated jointly in an exploratory multivariable logistic regression model to assess prognostic variables on survival. Results In the primary intention-to-treat (ITT) phase 2 population, 180/301 (59.8%) subjects received tocilizumab, and 67 deaths were observed overall. Lethality rates were equal to 18.4% (97.5% CI: 13.6–24.0, P = 0.52) and 22.4% (97.5% CI: 17.2–28.3, P < 0.001) at 14 and 30 days, respectively. Lethality rates were lower in the validation dataset, that included 920 patients. No signal of specific drug toxicity was reported. In the exploratory multivariable logistic regression analysis, older age and lower PaO2/FiO2 ratio negatively affected survival, while the concurrent use of steroids was associated with greater survival. A statistically significant interaction was found between tocilizumab and respiratory support, suggesting that tocilizumab might be more effective in patients not requiring mechanical respiratory support at baseline. Conclusions Tocilizumab reduced lethality rate at 30 days compared with null hypothesis, without significant toxicity. Possibly, this effect could be limited to patients not requiring mechanical respiratory support at baseline. Registration EudraCT (2020-001110-38); (NCT04317092).


Select your citation style and then place your mouse over the citation text to select it.
Perrone, Francesco; Piccirillo, Maria Carmela; Ascierto, Paolo Antonio; Salvarani, Carlo; Parrella, Roberto; Marata, Anna Maria; et al. (2020): Tocilizumab for patients with COVID-19 pneumonia. The single-arm TOCIVID-19 prospective trial. figshare. Collection.



Usage metrics

Journal of Translational Medicine


Francesco Perrone
Maria Carmela Piccirillo
Paolo Antonio Ascierto
Carlo Salvarani
Roberto Parrella
Anna Maria Marata
Patrizia Popoli
Laurenzia Ferraris
Massimiliano M. Marrocco-Trischitta
Diego Ripamonti
Francesca Binda
Paolo Bonfanti
Nicola Squillace
Francesco Castelli
Maria Lorenza Muiesan
Miriam Lichtner
Carlo Calzetti
Nicola Duccio Salerno
Luigi Atripaldi
Marco Cascella
need help?